Ludwig-Maximilians-University, Clinic Großhadern, Munich, Germany.
Cancer Metastasis Rev. 2012 Jun;31(1-2):235-46. doi: 10.1007/s10555-011-9343-7.
Our understanding of the role of lymph nodes (LN) in the metastasization process (MET) is marginal. Positive LNs (pLN) are the most important prognostic factor and lymph node dissection (LND) is still standard practice in primary treatment. However, up to now, there is almost no evidence that elective LND has a survival benefit. Based on many clinical and experimental findings, we propose that tumor foci in regional LN are incapable of metastasization and can therefore not infiltrate further LN and organs. Available data demonstrate a very early infiltration of MET capable tumor cells from the primary tumor into regional LN, and thereafter an increased probability of subsequent LN infiltrations. Disparate growth rates of the first versus subsequent infiltrating tumors as well as the asymptotic growth and prognosis of large tumor foci in LN explain many clinical observations for solid tumors. The consequence of the hypothesis "pLN do not metastasize" would impact clinical treatment and research and contribute to understanding the mounting evidence against LND.
我们对淋巴结(LN)在转移过程(MET)中的作用的理解是有限的。阳性淋巴结(pLN)是最重要的预后因素,淋巴结清扫(LND)在原发性治疗中仍然是标准做法。然而,到目前为止,几乎没有证据表明选择性 LND 具有生存获益。基于许多临床和实验发现,我们提出局部淋巴结中的肿瘤灶不能转移,因此不能进一步浸润淋巴结和器官。现有数据表明,MET 有能力的肿瘤细胞从原发性肿瘤非常早期就浸润到区域性 LN,此后随后 LN 浸润的概率增加。原发肿瘤与后续浸润肿瘤的生长速度不同,以及 LN 中大肿瘤灶的渐近生长和预后解释了许多实体瘤的临床观察。“pLN 不转移”这一假设的结果将影响临床治疗和研究,并有助于理解越来越多的证据反对 LND。